News Agency
Men's Weekly

Actinogen XanaCIDD Phase 2a trial in patients with depression and cognitive impairment: enrolment accelerating and on track for results in second quarter of 2024

  • Written by PR Newswire
Actinogen XanaCIDD Phase 2a trial in patients with depression and cognitive impairment: enrolment accelerating and on track for results in second quarter of 2024

US$3.2 million (A$4.8m) R&D tax incentive rebate received from Australian Tax Office and XanaMIA Phase 2b Alzheimer's disease trial to commence shortly with initial results expected in first half of 2025  

SYDNEY, Nov. 28, 2023 /PRNewswire/ -- Actinogen Medical Limited (ASX: ACW) announces that enrolment in the XanaCIDD Phase 2a...

Read more: Actinogen XanaCIDD Phase 2a trial in patients with depression and cognitive impairment: enrolment...

Hard Chrome Plating: Enhancing Durability And Performance In Industrial Components

In industries where equipment is exposed to constant friction, pressure, and harsh operating conditions, surface protection becomes critical to performance and longevity. Hard chrome plating is a specialised surface treatment process widely used to improve wear resistance, reduce friction, and extend... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion